Product Name Dehydroevodiamine
CAS No.: 67909-49-3
Catalog No.: CFN90944
Molecular Formula: C19H15N3O
Molecular Weight: 301.4 g/mol
Purity: >=98%
Type of Compound: Alkaloids
Physical Desc.: Yellow powder
Targets: Beta Amyloid | NOS | COX | PGE | NF-kB
Source: The fruits of Evodia rutaecarpa.
Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Price: $100/20mg
Dehydroevodiamine has anticholinesterase activity and an anti-amnesic effect, it also may be a novel and effective ligand for improvement of beta-amyloid type amnesia. Dehydroevodiamine has antiarrhythmic, and anti-inflammatory properties, the effect of dehydroevodiamine-mediated inhibition of the expression LPS-induced iNOS and COX-2 genes is due to under the suppression of NF-kappaB activation in the transcriptional level.
Inquire / Order:
Technical Inquiries:
Tel: +86-27-84237783
Fax: +86-27-84254680

1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to:

The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
  • Biochem Biophys Res Commun.2018, 505(1):194-200
  • Academic J of Second Military Medical University2018, 39(11)
  • J Biol Chem.2014, 289(3):1723-31
  • Food Chem.2019, 274:345-350
  • J Ethnopharmacol.2019, 236:31-41
  • Korean Journal of Pharmacognosy2017, 48(4):320-328
  • Biol Pharm Bull.2018, 41(11):1645-1651
  • J Ethnopharmacol.2017, 197:157-164
  • Chemistry of Plant Materials.2019, 129-136
  • United States Patent Application2020, 20200038363
  • Rutaecarpine

    Catalog No: CFN97337
    CAS No: 84-26-4
    Price: $40/20mg

    Catalog No: CFN96232
    CAS No: 163815-35-8
    Price: Inquiry(

    Catalog No: CFN98895
    CAS No: 53600-24-1
    Price: Inquiry(

    Catalog No: CFN99993
    CAS No: 518-17-2
    Price: $40/20mg
    Dehydroevodiamine hydrochloride

    Catalog No: CFN96360
    CAS No: 75853-60-0
    Price: Inquiry(

    Catalog No: CFN90944
    CAS No: 67909-49-3
    Price: $100/20mg
    J Ethnopharmacol. 2014 May 14;153(3):753-62.
    Antiarrhythmic effects of dehydroevodiamine in isolated human myocardium and cardiomyocytes.[Pubmed: 24680993 ]
    Dehydroevodiamine alkaloid (DeHE), a bioactive component of the Chinese herbal medicine Wu-Chu-Yu (Evodiae frutus), exerted antiarrhythmic effect in guinea-pig ventricular myocytes. We further characterize the electromechanical effects of DeHE in the human atrial and ventricular tissues obtained from hearts of patients undergoing corrective cardiac surgery or heart transplantation.
    The transmembrane potentials of human myocardia were recorded with a traditional microelectrode technique while sarcolemmal Na(+) and Ca(2+) currents in single human cardiomyocytes were measured by a whole-cell patch-clamp technique. The intracellular pH (pHi) and Na(+)-H(+) exchanger (NHE) activity were determined using BCECF-fluorescence in human atria. In human atria, DeHE (0.1-0.3 μM) depressed upstroke velocity, amplitude of action potential, and contractile force, both in slow and fast response action potential. Moreover, the similar depressant effects of DeHE were found in human ventricular myocardium. Both in isolated human atrial and ventricular myocytes, DeHE (0.1-1 μM) reversibly, concentration-dependently decreased the Na(+) and Ca(2+)currents. Moreover, DeHE (0.1 and 0.3 μM) suppressed delayed afterdepolarizations and aftercontractions, induced by epinephrine and high [Ca(2+)]o in atria. In human ventricular myocardium, the strophanthidin-induced triggered activities were attenuated by pretreating DeHE (0.3 μM). The resting pHi and NHE activity were also significantly increased by DeHE (0.1-0.3 μM).
    We concluded for the first time that, in the human hearts, DeHE could antagonize triggered arrhythmias induced by cardiotonic agents through a general reduction of the Na(+) and Ca(2+) inward currents, while increase of resting pHi and NHE activity.
    Eur J Pharmacol. 2001 Feb 16;413(2-3):221-5.
    Dehydroevodiamine attenuates beta-amyloid peptide-induced amnesia in mice.[Pubmed: 11226396]
    Dehydroevodiamine has been reported to have anticholinesterase activity and an anti-amnesic effect.
    This study examined the effects of Dehydroevodiamine on scopolamine- and beta-amyloid peptide-(25--35)-induced amnesia in mice, using a step-through passive avoidance test. Similarly to the cholinesterase inhibitor, physostigmine (0.03--0.3 mg/kg, i.p.), Dehydroevodiamine (0.75--12.0 mg/kg, i.p.) administered 30 min before the training trial, immediately after the training trial, and 30 min before the retention test significantly improved scopolamine- and beta-amyloid peptide-(25--35)-induced amnesia. In beta-amyloid peptide-(25--35)-induced amnesia, the rank order of anti-amnesic potency in these three administration schedules for Dehydroevodiamine was different from that for physostigmine. Furthermore, Dehydroevodiamine was more potent to improve beta-amyloid peptide-(25--35)-induced amnesia than scopolamine-induced amnesia when administered before the training trial.
    These results suggested that Dehydroevodiamine may have an action other than that of an anticholinesterase and may be a novel and effective ligand for improvement of beta-amyloid type amnesia.
    Life Sci. 2006 Jul 10;79(7):695-701.
    Inhibition of lipopolysaccharide-induced iNOS and COX-2 expression by dehydroevodiamine through suppression of NF-kappaB activation in RAW 264.7 macrophages.[Pubmed: 16554073 ]
    Dehydroevodiamine is a major bioactive quinazoline alkaloid isolated from Evodiae Fructus.
    We investigated the anti-inflammatory properties of Dehydroevodiamine in RAW 264.7 murine macrophages. The results indicated that Dehydroevodiamine inhibited the expression of LPS-induced iNOS and COX-2 proteins and suppressed also their mRNAs from RT-PCR experiment on RAW 264.7 cells. Furthermore, this compound inhibited the level of LPS-stimulated prostaglandin E2 (PGE2) and LPS-induced nuclear factor-kappa B (NF-kappaB).
    Therefore, we suggested that the effect of Dehydroevodiamine-mediated inhibition of the expression LPS-induced iNOS and COX-2 genes is due to under the suppression of NF-kappaB activation in the transcriptional level.

    Catalog No: CFN97160
    CAS No: 6807-83-6
    Price: $128/20mg

    Catalog No: CFN92007
    CAS No: 19202-36-9
    Price: $318/10mg
    Chrysin 6-C-arabinoside 8-C-glucoside

    Catalog No: CFN92284
    CAS No: 185145-33-9
    Price: $368/5mg
    Magnolignan A

    Catalog No: CFN96188
    CAS No: 93673-81-5
    Price: $388/5mg
    Kaempferol 7-O-rhamnoside

    Catalog No: CFN96224
    CAS No: 20196-89-8
    Price: $338/5mg
    Carasinol B

    Catalog No: CFN95042
    CAS No: 777857-86-0
    Price: $333/5mg
    6''-O-acetylsaikosaponin A

    Catalog No: CFN95086
    CAS No: 64340-46-1
    Price: $268/10mg
    Pueroside C

    Catalog No: CFN95156
    CAS No: 112343-16-5
    Price: $368/5mg
    Licoricesaponin H2

    Catalog No: CFN95173
    CAS No: 118441-85-3
    Price: $218/10mg
    New compound 4

    Catalog No: CFN95185
    CAS No: N/A
    Price: $368/5mg